Merck & Co. stock gains on FDA approval and higher sales
Published on 09/03/2026 at 07:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. stock (ISIN US58933Y1055) traded at USD 150.78 on September 2, 2026, with a market value of USD 369.73 billion and a 52-week range of USD 77.58 to USD 156.92. The latest move came after Merck said it will participate in the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, at 2:15 p.m. ET.
Sales and guidance moved up
For Q2 2026, Merck reported sales of USD 16.61 billion, up 5 percent from USD 15.81 billion a year earlier. Pharmaceutical sales reached USD 14.76 billion, and Animal Health contributed USD 1.78 billion, up 8 percent.
The company also lifted its 2026 sales outlook to USD 66.3 billion to USD 67.3 billion from a prior range of USD 65.8 billion to USD 67.0 billion. At the same time, non-GAAP EPS guidance was cut to USD 2.66 to USD 2.76 from USD 5.04 to USD 5.16 because of one-time business-development charges.
Keytruda still dominates
Keytruda and Keytruda Qlex generated USD 8.37 billion in quarterly sales in Q2 2026, equal to roughly half of Merck's total revenue. The cancer franchise remains the main earnings engine, even as the guidance reset shows how much near-term profit is being absorbed by charges tied to new deals.
Merck pipeline and conference outlook
Merck will use the September 9, 2026 investor conference to discuss its latest operating trends, pipeline progress and capital allocation priorities.
Conference date in September
Merck said Caroline Litchfield and Dean Y. Li are scheduled to join the fireside chat on September 9, 2026, at 2:15 p.m. ET. The date gives investors a near-term point for new comments on guidance, pipeline execution and the outlook for Keytruda.
Merck & Co. stock key data
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- Ticker: MRK
- Trading venue: NYSE
- Price (as of September 2, 2026, 10:49 a.m. EDT): USD 150.78
- Market capitalization: USD 369.73 billion (as of September 2, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
- Next earnings date: September 9, 2026
